Indian Pharma industry moving towards formulations

Indian Pharma industry is slowing moving up the value chain. Earlier it used to manufacture active pharmaceutical ingredient at low cost compared to world. Now with competition from China, which provides API at 15-20% low cost, it makes sense to shift focus elsewhere. Many top companies like Lupin, Novartis, Ranbaxy have less revenue stream from API than from formulations. There could also be the reason that formulation business has grown faster than APIs for some companies. API is low scale commodity with low margin. Moreover, with a large number of patent expiries in developed markets like the US and Europe, Indian companies, with skills to develop and manufacture low-cost generic drugs, see a much more lucrative opportunity there than utilising their capacities for manufacturing APIs.
Read More

  • No Image
    Surya Pharmaceutical Ltd

    Surya Pharmaceutical Limited was established in 1992, is now an integrated pharmaceuticals company in India. Its business focuses on Contract Manufacturing, Custom Synthesis, FT

  • No Image
    Susaah Laboratories Pvt Ltd

    Susaah Laboratories Pvt Ltd an ISO 9001: 2008 certified company, was incorporated on 2007 engaged in manufacturing of Antibiotic, Antihyperlipidemic, Antacid, Enzyme, Antiadren

  • No Image
    Suven Life Sciences Ltd

    Suven Life Sciences, in the business of design, manufacture and supply of Bulk Actives, Drug Intermediates & Fine Chemicals, catering to the needs of global Life Science Industr